1
|
Liu RR, Gu SZ, Zhou T, Lin LZ, Chen WC, Zhong DS, Liu TS, Yang N, Shen L, Xu SY, Lu N, Zhang Y, Gong ZL, Xu JM. [A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese patients with advanced solid tumors]. Zhonghua Zhong Liu Za Zhi 2023; 45:898-903. [PMID: 37875426 DOI: 10.3760/cma.j.cn112152-20220530-00373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 10/26/2023]
Abstract
Objective: To evaluate the safety and antitumor activity of envafolimab monotherapy in Chinese patients with advanced solid tumors. Methods: This open-label, multicenter phase I trial included dose escalation and dose expansion phases. In the dose escalation phase, patients received subcutaneous 0.1, 0.3, 1.0, 2.5, 5.0 or 10.0 mg/kg envafolimab once weekly (QW) following a modified "3+ 3" design. The dose expansion phase was performed in the 2.5 mg/kg and 5.0 mg/kg (QW) dose cohorts. Results: At November 25, 2019, a total of 287 patients received envafolimab treatment. During the dose escalation phase, no dose-limiting toxicities (DLT) was observed. In all dose cohorts, drug-related treatment-emergent adverse events (TEAEs) for all grades occurred in 75.3% of patients, and grade 3 or 4 occurred in 20.6% of patients. The incidence of immune-related adverse reactions (irAE) was 24.0% for all grades, the most common irAEs (≥2%) included hypothyroidism, hyperthyroidism, immune-associated hepatitis and rash. The incidence of injection site reactions was low (3.8%), all of which were grades 1-2. Among the 216 efficacy evaluable patients, the objective response rate (ORR) and disease control rate (DCR) were 11.6% and 43.1%, respectively. Median duration of response was 49.1 weeks (95% CI: 24.0, 49.3). Pharmacokinetic (PK) exposure to envafolimab is proportional to dose and median time to maximum plasma concentration is 72-120 hours based on the PK results from the dose escalation phase of the study. Conclusion: Subcutaneous envafolimab has a favorable safety and promising preliminary anti-tumor activity in Chinese patients with advanced solid tumors.
Collapse
Affiliation(s)
- R R Liu
- Department of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China
| | - S Z Gu
- Department of Interventional Radiology, Hunan Cancer Hospital, Changsha 410031, China
| | - T Zhou
- Department of Urology, Changhai Hospital of Shanghai, Shanghai 200433, China
| | - L Z Lin
- Cancer Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China
| | - W C Chen
- Department of Gastroenterology, First Affiliated Hospital to Soochow University, Suzhou 215006, China
| | - D S Zhong
- Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China
| | - T S Liu
- Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
| | - N Yang
- Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital, Changsha 410031, China
| | - L Shen
- Department of Gastrointestinal Oncology, Peking University Cancer Hospital, Beijing 100142, China
| | - S Y Xu
- 3D Medicines Co. Ltd, Chengdu 610036, China
| | - N Lu
- 3D Medicines Co. Ltd, Chengdu 610036, China
| | - Y Zhang
- 3D Medicines Co. Ltd, Chengdu 610036, China
| | - Z L Gong
- 3D Medicines Co. Ltd, Chengdu 610036, China
| | - J M Xu
- Department of Medical Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing 100071, China
| |
Collapse
|
2
|
Zhou Y, Jiang CQ, Qian Q, Zhang W, Wang XW, Zhang L, Yu XQ, Ding Z, Gong ZL, You SP. [A rare case of spontaneous transvaginal evisceration]. Zhonghua Wei Chang Wai Ke Za Zhi 2019; 22:1085-1086. [PMID: 31770841 DOI: 10.3760/cma.j.issn.1671-0274.2019.11.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
4
|
Zheng JJ, Gong ZL, Xue LS, Zhu XS, Luo JY. Lactose malabsorption and its ethnic differences in Hans and Uygurs. Chin Med J (Engl) 1988; 101:284-6. [PMID: 3138090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
6
|
Wang YM, Zheng JJ, Ren GR, Gong ZL, Huang FZ, Xue LS, Jiang JH, Zhu XS, Wu RY, Ling K. [Carcinoembryonic antigen and immunoglobin in gastric juice in the diagnosis of gastric cancer]. Zhonghua Zhong Liu Za Zhi 1986; 8:270-2. [PMID: 3757741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Levels of carcinoembryonic antigen (CEA) and immunoglobin (Ig) in gastric juice of 93 patients with benign and malignant gastric diseases were assayed. The CEA level in gastric cancer patients (55.73 +/- 38.26 ng/ml) was obviously higher than that in peptic ulcer (15.51 +/- 12.09 ng/ml) and superficial gastritis (26.96 +/- 20.17 ng/ml). But no significant difference was found between the CEA levels of gastric cancer and chronic atrophic gastritis (48.66 +/- 31.87 ng/ml). Also, elevated CEA was closely correlated to intestinal metaplasia. The positive rate of Ig was significantly higher in gastric cancer (IgG greater than or equal to 185 ug/ml, IgA greater than or equal to 100 ug/ml) than in benign gastric diseases. Although no correlation is present in the CEA and Ig in gastric juice, the combination of these two methods could improve the diagnostic accuracy. We believe that the two assays are worthy for screening gastric cancer from patients with high risk, and for identifying precancerous lesions.
Collapse
|
7
|
Wang YJ, Kang Y, Gong ZL, Mei YX, Xu JY, Meng LX, Zhao K, Li X, Hu ZH, Song ZZ. Hepatitis B vaccine in neonates: induction of anti-HBs immune response and interruption of maternal HBsAg transmission. Chin Med J (Engl) 1985; 98:265-70. [PMID: 3924520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|